Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

New analysis reveals insights on hypnagogic and hypnopompic hallucinations in narcolepsy patients treated with once-nightly sodium oxybate.

Phase 3 REST-ON Analysis Provides Insights Into Hypnagogic and Hypnopompic Hallucinations of Narcolepsy

Catch up on any of the neurology news headlines you may have missed over the course of May 2025, compiled all into one place by the NeurologyLive® team.

FDA Action Update, May 2025: Approval, Clearance, and Authorization

A newly presented actigraphy-based algorithm demonstrated high accuracy in detecting daytime naps, offering insights into napping behavior changes in patients with narcolepsy type 1.

Actigraphy-Based Nap Detection Algorithm Highlights Increased Napping in Narcolepsy Type 1, Reduced Napping With TAK-861

A recent analysis reveals the safety profile of once-nightly sodium oxybate for narcolepsy, highlighting low discontinuation rates and common adverse events.

Post-Hoc Analysis Gives Safety Insights on Switch From Twice-Nightly Oxybate to Once-Nightly Treatment

Senior Director, Patient Management, Care and Rehabilitation Research, National MS Society

The associate vice president of research at the National MS Society discussed a growing research initiative focused on defining and promoting evidence-based psychosocial wellness strategies for individuals with MS. [WATCH TIME: 6 minutes]

Expanding the Scope of Wellness Research in Multiple Sclerosis: Kathy Zackowski, PhD, OTR

Founder and Executive Director, Sumaira Foundation

Videos

The executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]

Investigating Treatment Differences of Off-Label and Marketed Therapies for NMOSD: Sumaira Ahmed

Department of Neurology, Mayo Clinic Health System Franciscan Health Care, in La Crosse, Wisconsin

The assistant professor of neurology at Mayo Clinic College of Medicine and Science outlined a case of myelin oligodendrocyte glycoprotein antibody-associated disease from diagnosis to long-term management. [WATCH TIME: 5 minutes]

A Case-Based Overview of Treatment Strategies for Relapse Prevention in MOGAD: Smathorn Thakolwiboon, MD

The associate vice president of research at National MS Society talked about the need for evidence-based wellness strategies in multiple sclerosis, particularly focusing on psychosocial interventions.

NeuroVoices: Kathy Zackowski, PhD, OTR, on Promoting Psychosocial Wellness Research in MS Care

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

Conference Archive

The AD/PD Alzheimer Disease and Parkinson Disease Conference features presentations related to the latest breakthroughs in translational research, drug development, early diagnosis, treatment, and clinical trials in Alzheimer, Parkinson, and other related neurological disorders.

The chief scientific officer at Quanterix gave a clinical overview on how the company’s Simoa platform enables ultrasensitive detection of neurodegeneration biomarkers in blood, transforming Alzheimer and Parkinson disease research. [WATCH TIME: 3 minutes]

Insights on Quanterix Simoa Assay to Diagnose Alzheimer Disease: Mark Roskey, PhD

AD/PD International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)

The Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress is hosted by the Parkinson & Movement Disorder (PMD) Alliance, in partnership with MedStar Georgetown University Hospital. It aims to provide discussion among clinicians of all types to enhance movement disorder clinical practices in a refreshing manner for patients, their support network, and clinicians.


The consultant neurologist at Fondazione Don Carlo Gnocchi ONLUS stressed how new clinical trial designs for cervical dystonia should incorporate more flexible and patient-centered approaches, including new measurement scales and the use of technology. [WATCH TIME: 5 minutes]

The Need for Flexibility and Patient-Centered Approaches in Clinical Trials for Cervical Dystonia: Anna Castagna, MD

Advanced Therapeutics in Movement and Related Disorders Congress (ATMRD)

The Alzheimer’s Association International Conference (AAIC) is the largest international meeting dedicated to advancing dementia science. It convenes basic science and clinical researchers, next-generation investigators, clinicians, and the research community to share research discoveries toward preventing and treating Alzheimer disease.

The disease area stronghold leader in neurodegeneration at Johnson & Johnson discussed data presented at AAIC 2024 highlighting different subtypes of Alzheimer disease that may lead to more personalized treatments. [WATCH TIME: 4 minutes]

Distinct Alzheimer Disease Subtypes Using Proteomic Fingerprints: Fiona Elwood, PhD

Alzheimer's Association International Conference (AAIC)

The Alzheimer's Drug Discovery Foundation International Conference showcases the innovative approaches of Alzheimer’s Drug Discovery Foundation’s (ADDF) funded scientists and their data, as well as guest presentations on the latest research in Alzheimer disease.

Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.

Krista Lanctot, PhD: Managing Patients with Agitation

Alzheimer's Drug Discovery Foundation International Conference (ADDF)

The American Academy of Neurology (AAN) Annual Meeting brings together an international attendance of the neurology committee to promote the highest quality patient-centered neurologic care, convey the latest advances, and enhance career satisfaction.

Josh Bryson, PhD, head of Medical Affairs at Argenx, discussed the safety profile of efgartigimod in light of recent FAERS-based infection data and offered clinical context for patient care.

Evaluating Risk: Clarifying the Safety Data Behind Efgartigimod

American Academy of Neurology Annual Meeting (AAN)

The American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting offers opportunities for physicians, technologists, and other healthcare professionals to learn about the latest in neuromuscular, musculoskeletal, and electrodiagnostic medicine.

Rachana K. Gandhi Mehta, MBBS, an assistant professor of neurology at Wake Forest School of Medicine, discussed a new, innovative trial assessing the therapeutic potential of self-administered subcutaneous rozanolixizumab as a treatment for myasthenia gravis.

Empowering Patients: Exploring Self-Administration of Rozanolixizumab for Myasthenia Gravis

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM)

The American Epilepsy Society (AES) Annual Meeting brings together healthcare providers, scientists, advocates, industry, and other professionals dedicated to better outcomes for people with epilepsy to connect on the latest research and data in epilepsy and seizure disorders.

Jonathon Parker, MD, PhD, an assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona, provided commentary on the promise and roadblocks behind stem cell approaches in epilepsy.

Stem Cells in Epilepsy: Innovations and Challenges in Neurosurgical Treatment

American Epilepsy Society Annual Meeting (AES)

The American Headache Society (AHS) Annual Scientific Meeting is designed for physicians, psychologists, scientists, researchers, physician assistants, nurse practitioners, and other health professionals involved in the care of patients with head, neck, and orofacial pain. It aims to disseminate the most up-to-date research and scientific advances underlying the practice of headache medicine.

The associate professor of neurology at Mayo Clinic College of Medicine discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine. [WATCH TIME: 4 minutes]

Assessing Long-Term Benefit of Eptinezumab for Chronic Migraine: Amaal Starling, MD, FAHS, FAAN

American Headache Society Annual Scientific Meeting (AHS)

The American Neurological Association Annual Meeting convenes top academic neurologists and neuroscientists, aiming to highlight groundbreaking conceptual and therapeutic advances in a variety of neurologic disease states, among other presentations.

Erik Musiek, MD, PhD, a professor of neurology at Washington University in St. Louis, provided clinical insight on a presentation from ANA 2024 highlighting the intricate relationship between circadian rhythms, glial activation, and neuroinflammation in Alzheimer disease.

Exploring the Impact of Circadian Rhythms on Glial Function and Alzheimer Disease

American Neurological Association Annual Meeting (ANA)

The American Neuropsychiatric Association (ANPA) Annual Meeting brings together professionals in behavioral neurology, neuropsychiatry, neuropsychology, and clinical neuroscience to improve the lives of people with disorders at the interface of psychiatry and neurology.

The American Neuropsychiatric Association (ANPA) is holding their 27th Annual Meeting from March 16-19, 2016.

Upcoming ANPA Meeting

American Neuropsychiatric Association Annual Meeting (ANPA)

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS. Every third year, it meets collectively with its European counterpart, ECTRIMS.

The professor of neurology and neurosurgery at McGill University discussed the evolution of multiple sclerosis treatment, the need for earlier intervention, and the pressing scientific questions surrounding neuroinflammation. [WATCH TIME: 4 minutes]

Advancing MS Care Through Early Intervention and Deeper CNS Insights: Jack P. Antel, MD

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

The Annual Meeting of the Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium brings together clinicians, researchers, and members of the NEALS Consortium to share the latest data and findings in the care of ALS, and discuss the hottest topics in neuromuscular medicine.

The chief scientific officer at Athira Pharma talked about new preclinical results presented at the 2023 NEALS Annual Meeting on the investigational therapy ATH-1105 for patients with amyotrophic lateral sclerosis. [WATCH TIME: 5 minutes] 

Targeting Neurotrophic Factors and Preclinical Results of ALS Agent ATH-11055: Kevin Church, PhD

Annual Northeast ALS Consortium Meeting (NEALS)

The annual Scientific and Family Conference is a four-day neuromuscular conference for both in-person and virtual stakeholders in congenital muscular dystrophy, nemaline myopathy, and titin-related disorders.

Rachel Alvarez and Gustavo Dziewczapolski, PhD, of Cure CMD spoke about the benefits of attending the biennial Scientific & Family Conference to learn more about congenital muscle diseases and interact with the patient community.

Cure CMD: Benefits of the Biennial SciFam Conference

CMD Scientific and Family Conference

The Child Neurology Society Annual Meeting is held to bring clinicians and researchers together to collaborate and share the latest research and data, and discuss the hottest topics in pediatric neurology.

Analysis of long-term safety of intranasal diazepam shows favorable results in children and adolescents with cluster or acute, repetitive seizures.

Intranasal Diazepam Safe, Tolerable in Pediatric Epilepsy

Child Neurology Society Annual Meeting (CNS)

The Clinical Trials on Alzheimer's Disease Conference (CTAD) includes a focus on Alzheimer disease (AD) therapeutic trials, featuring leaders in AD research from industry and academia with an aim of forming partnerships to progress the development of effective treatments to fight the disease.

The chair of psychiatry at Tufts University School of Medicine discussed ongoing research exploring the potential of cannabinoids in treating agitation in Alzheimer disease. [WATCH TIME: 5 minutes]

Clarifying the Role of Cannabinoids in Agitation Management for Alzheimer Disease: Brent Forester, MD, MSc

Clinical Trials on Alzheimer's Disease Conference (CTAD)

The Congress of the European Sleep Research Society brings together a worldwide attendance of sleep medicine specialists, researchers, and clinicians to advance the treatment and research for sleep disorders.

The Professor of Medicine at the University of New South Wales highlighted the latest knowledge in sleep apnea phenotyping and its crucial role in the development of targeted pharmacotherapies to treat OSA.

Phenotyping as a Rational for Drug Development in Obstructive Sleep Apnea

Congress of the European Sleep Research Society (ESRS)

The Consortium of Multiple Sclerosis Centers Annual Meeting is the leading research and educational conference for multiple sclerosis healthcare professionals of all disciplines in North America.

Sam Hooshmand, DO, assistant professor of neurology at the Medical College of Wisconsin, discussed the complexities of defining, diagnosing, and managing advanced MS.

Clinical Insight on Challenges and Evolving Strategies in Advanced Multiple Sclerosis Care

Consortium of Multiple Sclerosis Centers Annual Meeting (CMSC)

The European Academy of Neurology's Annual Congress is held to bring clinicians and researchers together to collaborate and share the latest research and data, and discuss the hottest topics in neurologic medicine.

The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks. 

Generalized Myasthenia Gravis Symptom Severity Reduced Through Ravulizumab Treatment

European Academy of Neurology Congress (EAN)

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress annually brings together clinicians and researchers in multiple sclerosis (MS) to share the latest data and literature, and interact on the hottest topics in clinical care and therapeutics. Every third year, it meets collectively with its North American counterpart, ACTRIMS.

At ECTRIMS 2024, the postdoctoral research assistant at Charité University Berlin discussed how the updated diagnostic criteria aim to address gaps in diagnosing and treating overlapping autoimmune conditions. [WATCH TIME: 4 minutes]

Implications of New Multiple Sclerosis Criteria on Overlapping Autoimmune Conditions: Joseph Kuchling, MD

European Committee for Treatment and Research in Multiple Sclerosis Congress (ECTRIMS)

 State of the Science Summits are short meetings designed to educate neurologists and advanced practice providers on the clinical benefits associated with the new science driving new thinking, featuring renowned faculty who focus on the most relevant topics to ultimately improve patient care.

>>Click here to check out the latest or next event(s)

The director of the Mellen Center for MS at Cleveland Clinic offered an overview of the State of the Science Summit that was held on November 10, 2022, featuring a panel of expert clinicians. [WATCH TIME: 4 minutes]

Linking the Latest Research to Clinical Care in MS: Robert Bermel, MD

Institutional Perspectives in Neurology: Multiple Sclerosis

The Annual International Congress on the Future of Neurology

 showcases the most recent advancements in neurologic disorders. Faculty present practice-changing clinical data, and discuss strategies for incorporating new therapies into clinical practice, and offer a comprehensive overview of pharmacological and nonpharmacological modalities.

The associate professor of neurology at NYU Grossman School of Medicine talked about the need for increased awareness in the medical community to address the underutilization of surgical interventions for refractory focal epilepsy. [WATCH TIME: 4 minutes]

Narrowing the Treatment Gap and Raising Awareness of Surgical Options for Epilepsy: Patricia C. Dugan, MD

International Congress on the Future of Neurology (IFN)

The International Epilepsy Congress is put on annually by the International League Against Epilepsy and features a variety of experts in the care and management of epilepsy and seizure disorders.

The director of the Pediatric Epilepsy Center at UCSF provided perspective on the advances in the treatment of Dravet syndrome, emerging research concepts in the field, and the influence of genetic testing. [WATCH TIME: 5 minutes]

Shift in Treatment Paradigm for Dravet Syndrome: Joseph Sullivan, MD

International Epilepsy Congress (IEC)

The International Parkinson and Movement Disorder Society (MDS) gathers thousands of clinicians, researchers, trainees, and industry supporters to discuss the diagnosis and treatment of movement disorders on an annual basis.

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

Phase 2a Trial to Test Effects of Antiseizure Medication Lamotrigine in Dementia With Lewy Bodies

International Parkinson and Movement Disorders Society Congress (MDS)

The International Stroke Conference features the annual dissemination of the latest stroke and brain health science to researchers, clinicians, and scientists. It is hosted by the American Heart Association/American Stroke Association.

RapidAI identified 98% of LVOs compared to 74% by Viz LVO, while also correctly identifying 94% of LVO-negative cases compared to 91% for Viz.

RapidAI Outperforms VizAI in Detecting Large Vessel Occlusion

International Stroke Conference (ISC)

The Muscular Dystrophy Association (MDA) Clinical and Scientific Conference highlights unprecedented research advancements and clinical achievements in neuromuscular disorders and includes patients, physicians, researchers, and more, with topics of discussion focusing on all aspects of preclinical, translational, and clinical research and care.

Phil Lambert, PhD, chief scientific officer at Satellos Bioscience, discusses the rationale and early clinical progress of SAT-3247, a novel regenerative therapy targeting muscle stem cells in Duchenne muscular dystrophy.